Press releaseGlobe Newswire
Aclarion
ACONW · NASDAQ
$0.0258−$0.0047 (−15.41%)TodayMarket closed ·
Prev close $0.0305
Latest news
- Press releaseGlobe Newswire
Aclarion to Present at the 20th Annual LD Micro Main Event
- Press releaseGlobe Newswire
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
- Press releaseGlobe Newswire
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
- Press releaseGlobe Newswire
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
- Press releaseGlobe Newswire
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
- Press releaseGlobe Newswire
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
- Press releaseGlobe Newswire
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
- Press releaseGlobe Newswire
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
- Press releaseGlobe Newswire
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
- Press releaseGlobe Newswire
Aclarion Announces $2.5 Million Stock Repurchase Plan
- Press releaseGlobe Newswire
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
- Press releaseGlobe Newswire
Aclarion Receives Pinnacle Award for AI Innovation
- Press releaseGlobe Newswire
Aclarion Announces Agreement with Weill Cornell Medicine
- Press releaseGlobe Newswire
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
- Press releaseGlobe Newswire
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
- Press releaseGlobe Newswire
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
- Press releaseGlobe Newswire
Aclarion CEO Brent Ness to Attend LSI USA 2026
- Press releaseGlobe Newswire
Aclarion Publishes 2026 Shareholder Letter from the Chairman
- Press releaseGlobe Newswire
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
- Press releaseGlobe Newswire
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
- Press releaseGlobe Newswire
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.